EcoR1 Capital and Director Oleg Nodelman Disclose 9.1% Stake in Aktis Oncology
AKTS is trading near its 52-week low of $19.02 (2.4% above the low) on light trading volume (0.1× avg).
Summary
EcoR1 Capital and director Oleg Nodelman have reported a 9.1% beneficial ownership in Aktis Oncology, signaling a significant investment and confidence in the company's prospects.
Key Events · Ownership and Investor Activity · AKTS
-
Significant Ownership Disclosure
EcoR1 Capital, LLC and its manager Oleg Nodelman, a director of Aktis Oncology, have filed an initial Schedule 13D, disclosing a 9.1% beneficial ownership stake in the company.
-
Substantial Investment Value
The reported stake, totaling 4,862,335 shares, represents a significant investment valued at approximately $94.69 million based on the current stock price.
-
Investment Rationale
The reporting persons acquired the securities for investment purposes, believing Aktis Oncology's shares represent an attractive opportunity.
-
Director's Conviction
Oleg Nodelman's dual role as a director and manager of the investing entity adds weight to the conviction behind this substantial stake, especially as the stock trades near its 52-week low.
Analysis · AKTS · Life Sciences
EcoR1 Capital, a prominent life sciences investment firm, along with its manager Oleg Nodelman, who also serves as a director of Aktis Oncology, has disclosed a significant 9.1% beneficial ownership stake. This initial Schedule 13D filing indicates a substantial long-term investment, with the reporting persons stating their belief that the company's securities represent an attractive investment opportunity. The timing of this disclosure, with the stock trading near its 52-week low, suggests strong conviction from a key institutional investor and insider.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKTS was trading at $19.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $19.02 to $29.16. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.